Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

112.91 +0.83 (+0.74%)
Streaming Delayed Price Updated: 1:42 PM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About Kymera Therapeutics ↗
 
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Where Kymera Therapeutics Stands With Analysts ↗
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
News headline image
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Recap: Kymera Therapeutics Q3 Earnings ↗
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
  Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). 
Via Benzinga
News headline image
Looking Into Kymera Therapeutics's Return On Capital Employed ↗
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26... 
Via Benzinga
News headline image
Where Kymera Therapeutics Stands With Analysts ↗
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock ↗
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
News headline image
Kymera Therapeutics: Q2 Earnings Insights ↗
  Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022 ↗
  
Via Benzinga
News headline image
Kymera Therapeutics Commences Initial-Stage Oncology Trials ↗
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.